IGNT-ingen technologies, inc

[ddblock808]

.Photo Release -- Ingen Launches the New Oxyview Pulse Oximeter
Another Giant Leap for Ingen


Buzz up! 0 Print..Companies:Ingen Technologies, Inc..Related Quotes
Symbol Price Change
IGNT.PK 0.0026 0.0000


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Wednesday January 6, 2010, 1:36 pm EST

YUCAIPA, Calif., Jan. 6, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer for the Oxyview Nasal Cannula, focused on the $4B Respiratory market for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries, announced today the introduction of the new Oxyview Pulse Oximeter.



A photo accompanying this release is available at GlobeNewswire, Inc.



The Oxyview Pulse Oximeter is a very important and common device to check patient blood-oxygen saturation (SpO2) level and pulse rate. As a small, compact, simple, reliable and durable physiological monitoring device, the Oxyview Pulse Oximeter greatly enhances patient care, and fits both Adult and Pediatric patients. This small & lightweight design has a measurement range of 70% - 100%, and requires two AAA batteries. It has a Resolution of 1% with a measurement accuracy of 70% - 100%: +/- 3%. Some of the features include a dual color OLED display, display SpO2, PR, Pulse bar and Plethysmogram, 6 display modes, low power consumption, automatic power off, battery-low indicator, and an adjustable brightness feature.



This dynamic new product is the most sophisticated and cost competitive pulse oximeter in the market today. The company is selling the new device for $88.00, and when patients purchase the Oxyview Nasal Cannula they will earn points and receive the new Oxyview Pulse Oximeter at a discount. The market for this device includes the home oxygen patient market and the hospital markets.



"This new device will greatly enhance our revenues with expected sales of $1M in 2010, and increased sales with GSA contracts and our new distribution. The new Oxyview Pulse Oximeter has features that no other oximeter can offer, and the price is far less than that of any other Oximeter in its class," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.



Oxyview Nasal Cannula - Home - Yucaipa, CA



Ingen Technologies,Inc. - Home



About Ingen: Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009, the company introduced the new Oxyview Nasal Cannula for adult, children and infants. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

[ddblock808]

Ingen CEO Interview on The Money Channel
Increase Sales of the Oxyview Product Line Through GPO Contracts


Buzz up! 0 Print..Companies:Ingen Technologies, Inc..Related Quotes
Symbol Price Change
IGNT.PK 0.00 0.00


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""} Press Release Source: Ingen Technologies, Inc. On Friday January 15, 2010, 7:15 am

YUCAIPA, Calif., Jan. 15, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced that they will engage Medical Strategies International (MSI) to increase sales of the Oxyview product line through GPO contracts. The company points to the increasing prevalence of respiratory diseases, emerging hospital markets, and developing world markets. The CEO will discuss this with host Steve Crowley today at 9:34AM eastern standard time on the world renowned Money Channel's American Scene Radio.



The company projects that the Oxyview Nasal Cannula will bring $10M in revenues, and the new Oxyview Pulse Oximeter an additional $1M in revenues in 2010.



The Money Channel // American Scene Radio // WallStreetCast



Ingen Technologies,Inc. - Home



About Ingen:



Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.



The Ingen Technologies, Inc. logo is available at GlobeNewswire, Inc.



Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.